Dan Dilks

Dan Dilks currently serves as the Senior Vice President of Business Development & Commercial at ACCUGENOMICS, where he leverages over 25 years of extensive experience in the life sciences and pharmaceutical sectors to drive strategic growth and innovation. In his role, Dan is instrumental in identifying and cultivating new market opportunities, forging key partnerships, and expanding the company's footprint in the rapidly evolving field of clinical genomics. His deep expertise in molecular biology, biotechnology, and diagnostics enables him to effectively communicate complex technical concepts to diverse stakeholders, ensuring alignment between product development and market needs.

At ACCUGENOMICS, Dan is focused on advancing the company's mission to improve the accuracy and performance of clinical sequencing, particularly in the detection of low abundance biomarkers. He oversees initiatives that demonstrate the analytical robustness of sequencing-based diagnostics, which are critical for delivering reliable results in patient care. His leadership in commercial strategy involves integrating cutting-edge technologies such as PCR, proteomics, and cell biology to optimize assay performance and expand clinical applications.

Dan’s ability to build strong relationships with healthcare providers, laboratory partners, and industry collaborators has been vital in accelerating the adoption of innovative genomic solutions. His consultative approach supports sales teams in developing tailored strategies that highlight the value of ACCUGENOMICS’ offerings, ultimately enhancing patient outcomes through precision diagnostics. With a keen focus on the intersection of scientific innovation and commercial success, Dan continues to position ACCUGENOMICS as a leader in the genomics and molecular diagnostics landscape.